Marianne Davies, NP, on Assessing Immunotherapy Toxicities in Lung Cancer Patients
Marianne Davies, NP, discusses making patients' oncology team their first line of contact should they develop any toxicities related to receiving treatment. Davies says this is important for patients so that the oncology team can assess whether it is an immune-related side effect, or an issue that can be dealt with by their primary care physician.
Marianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses why a patient's oncology team should be their first line of contact should they develop any toxicities related to receiving treatment. Davies says this is important for patients so that the oncology team can assess whether they are experiencing an immune-related side effect, or an issue that can be dealt with by their primary care physician.
Davies adds that some toxicities, such asn inflammatory pneumonitis, could appear as though it is simply an upper respitory infection, leading patients and their families to believe that the best course of action would be to see their primary care physician. Some resources for patients that may help them get a better grasp on symptoms of these toxicities include patient forums and online educational materials.
Kim Evaluates New Regimens for EGFR+ Lung Cancer
January 20th 2025During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Read More
Roundtable Roundup: Lung Cancer Molecular Testing and ALK-Targeted Treatment
January 18th 2025In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options for a patient with metastatic non–small cell lung cancer (NSCLC), with participants.
Read More
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
